Pediatrix Medical Group Reports Second Quarter Results

Rhea-AI Summary

Pediatrix Medical Group, Inc. (NYSE: MD) reported earnings from continuing operations of $0.36 per share for Q2 2022, with Adjusted EPS of $0.47. The company achieved net revenue of $486 million, a 2.7% increase from the prior year, primarily due to acquisitions. However, same-unit revenue decreased by 1.3%. Operating expenses rose to $330.8 million, reflecting acquisitions. Adjusted EBITDA for Q2 was $66 million. Cash from continuing operations was $81.6 million. The company anticipates 2022 Adjusted EBITDA between $260-$270 million.

Positive

• Q2 2022 revenue increased by 2.7% YoY to $486 million.
• Adjusted EPS improved to $0.47 from $0.41 YoY.
• Adjusted EBITDA for Q2 remained stable at $66 million.
• Cash from continuing operations for Q2 was $81.6 million.

Negative

• Same-unit revenue decreased by 1.3% in Q2.
• Income from continuing operations decreased to $30.7 million compared to $35.9 million in the prior-year period.
• Cash and cash equivalents fell significantly from $387.4 million to $14.1 million YoY.

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)-- Pediatrix Medical Group, Inc. (NYSE: MD), the nation’s leading provider of highly specialized health care for women, children and babies, today reported earnings from continuing operations of $0.36 per share for the three months ended June 30, 2022. On a non-GAAP basis, Pediatrix reported Adjusted EPS from continuing operations of $0.47.

For the 2022 second quarter, Pediatrix reported the following results from continuing operations:

• Net revenue of $486 million;
• Income from continuing operations of $31 million; and
• Adjusted EBITDA of $66 million.

“Our bottom line results reflected modest volume growth and continued operating efficiency,” said Mark S. Ordan, Chief Executive Officer of Pediatrix Medical Group. “Our formal return to the Pediatrix name and brand reflects our commitment to the highest quality care possible for women, babies and children, and that is where 100 percent of our efforts are focused.”

Operating Results from Continuing Operations – Three Months Ended June 30, 2022

Pediatrix’s net revenue for the three months ended June 30, 2022 was $486.0 million, compared to $473.0 million for the prior-year period. Pediatrix’s revenue growth was driven by net acquisition activity, modestly offset by an overall same-unit revenue decrease of 1.3 percent.

Same-unit revenue attributable to patient volume increased by 0.6 percent for the 2022 second quarter as compared to the prior-year period, with growth in neonatology and other pediatric services partially offset by slight declines in maternal-fetal medicine and pediatric cardiology services. Shown below are year-over-year percentage changes in certain same-unit volume statistics for the three and six months ended June 30, 2022. (Note: figures in the below table reflect contributions only to net patient service revenue and exclude other contributions to total same-unit revenue, including contract and administrative fees.)

		Three Months Ended June 30, 2022		Six Months Ended June 30, 2022
Hospital-based patient services		0.7%		2.0%
Office-based patient services		0.7%		3.1%
Neonatology services (within hospital-based services):
Total births		0.0%		1.9%
Neonatal intensive care unit (NICU) days		0.4%		1.3%

Same-unit revenue from net reimbursement-related factors declined by 1.9 percent for the 2022 second quarter as compared to the prior-year period. This net decrease primarily reflects a modest decline in the percentage of services reimbursed by commercial and other non-government payors compared to the prior-year period and the timing of certain revenue cycle management transition activities, partially offset by increases in contract and administrative fees and funds received under the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act. The percentage of services reimbursed by commercial and other non-government payors declined by approximately 120 basis points compared to the prior-year period. For the 2022 second quarter, the Company recorded $0.7 million of miscellaneous revenue from funds received under the CARES Act, which increased the Company’s same-unit revenue from net reimbursement-related factors by 0.2 percent for the three months ended June 30, 2022.

For the 2022 second quarter, practice salaries and benefits expense was $330.8 million, compared to $317.0 million for the prior-year period. This increase primarily reflects acquisitions completed over the past year.

For the 2022 second quarter, general and administrative expenses were $61.2 million, as compared to $71.0 million for the prior-year period. The net decrease of $9.8 million is primarily related to lower professional fees, including legal fees, as well as a net savings in revenue cycle management expenses.

For the second quarter of 2022, transformational and restructuring related expenses totaled $5.3 million, compared to $9.9 million for the second quarter of 2021. The expense recorded during the second quarter of 2022 related predominantly to position eliminations.

Adjusted EBITDA from continuing operations, which is defined as earnings from continuing operations before interest, taxes, depreciation and amortization, and transformational and restructuring related expenses, was $65.6 million for the 2022 second quarter, compared to $65.5 million for the prior-year period. Funds received from the provider relief fund established by the CARES Act favorably impacted Adjusted EBITDA by approximately $0.5 million for the second quarter of 2022.

Depreciation and amortization expense was $8.8 million for the second quarter of 2022 compared to $8.1 million for the second quarter of 2021.

Investment and other income was $0.8 million for the second quarter of 2022, compared to $4.2 million for the second quarter of 2021. This decrease primarily reflects the reimbursement received in the prior year period related to the transition services provided to the buyers of the Company’s divested medical groups.

Interest expense was $8.4 million for the second quarter of 2022 compared to $16.9 million for the second quarter of 2021. This decrease reflects lower total debt and lower interest rates from the Company’s previously-disclosed refinancing transactions completed during the first quarter of 2022.

Pediatrix generated income from continuing operations of $30.7 million, or $0.36 per diluted share, for the 2022 second quarter, based on a weighted average 85.6 million shares outstanding. This compares with income from continuing operations of $30.5 million, or $0.36 per diluted share, for the 2021 second quarter, based on a weighted average 85.9 million shares outstanding.

For the second quarter of 2022, Pediatrix reported Adjusted EPS from continuing operations of $0.47, compared to $0.41 for the second quarter of 2021. For these periods, Adjusted EPS from continuing operations is defined as diluted income from continuing operations per common and common equivalent share excluding non-cash amortization expense, stock-based compensation expense, transformational and restructuring related expenses, and discrete tax events, and for the prior year period also excludes the gain on sale of building.

Operating Results from Continuing Operations – Six Months Ended June 30, 2022

For the six months ended June 30, 2022, Pediatrix generated revenue from continuing operations of $968.3 million, compared to $919.7 million for the prior-year period. Adjusted EBITDA from continuing operations for the six months ended June 30, 2022 was $116.2 million, compared to $111.0 million for the prior year. Pediatrix generated income from continuing operations of $9.8 million, or $0.11 per share, for the six months ended June 30, 2022, based on a weighted average 85.9 million shares outstanding, which compares to income from continuing operations of $35.9 million, or $0.42 per share, based on a weighted average 85.7 million shares outstanding for the first six months of 2021. For the six months ended June 30, 2022, Pediatrix reported Adjusted EPS from continuing operations of $0.79, compared to $0.65 in the same period of 2021.

Financial Position and Cash Flow – Continuing Operations

Pediatrix had cash and cash equivalents of $14.1 million at June 30, 2022, compared to $387.4 million on December 31, 2021, and net accounts receivable were $307.2 million. As previously disclosed, during the first quarter of 2022 the Company used cash on hand, together with proceeds from the new issuance of debt, to redeem its $1.0 billion in outstanding principal amount of 6.25% Senior Notes due 2027 and pay related fees and expenses.

For the second quarter of 2022, Pediatrix generated cash from continuing operations of $81.6 million, compared to $70.4 million for the second quarter of 2021. During the second quarter of 2022, the Company used $64.4 million to fund the repurchase of 3.3 million shares under the Company’s previously announced repurchase program, $6.6 million to fund capital expenditures and $3 million to fund one practice acquisition.

At June 30, 2022, Pediatrix had total debt outstanding of $800 million, consisting of its $400 million in 5.375% Senior Notes due 2030; $247 million in borrowings under its Term A Loan; and $153 million in borrowings under its revolving line of credit.

Non-GAAP Measures

A reconciliation of Adjusted EBITDA from continuing operations and Adjusted EPS from continuing operations to the most directly comparable GAAP measures for the three and six months ended June 30, 2022 and 2021 is provided in the financial tables of this press release.

2022 Outlook

Pediatrix anticipates that its 2022 Adjusted EBITDA, as defined above, will be in a range of $260 million to $270 million. This outlook reflects Adjusted EBITDA for the first six months of 2022 of $116.2 million.

Earnings Conference Call

Pediatrix will host an investor conference call to discuss the quarterly results at 9 a.m., ET today. The conference call Webcast may be accessed from the Company’s Website, www.pediatrix.com. A telephone replay of the conference call will be available from 12:45 p.m. ET today through midnight ET August 18, 2022 by dialing 866.207.1041, access Code 9245025. The replay will also be available at www.pediatrix.com.

ABOUT PEDIATRIX MEDICAL GROUP

Pediatrix® Medical Group, Inc. (NYSE:MD) is the nation’s leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Specialties include obstetrics, maternal-fetal medicine and neonatology complemented by more than 20 pediatric subspecialties, as well as a newly expanded area of pediatric primary and urgent care clinics. The group’s high-quality, evidence-based care is bolstered by significant investments in research, education, quality-improvement and safety initiatives. The physician-led company was founded in 1979 as a single neonatology practice and today provides its highly specialized and often critical care services through more than 4,800 affiliated physicians and other clinicians in 37 states and Puerto Rico. To learn more about Pediatrix, visit www.pediatrix.com or follow us on Facebook, Instagram, LinkedIn, Twitter and the Pediatrix blog. Investment information can be found at www.pediatrix.com/investors.

Certain statements and information in this press release may be deemed to contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating to the Company’s objectives, plans and strategies, and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions, and are based on assumptions and assessments made by the Company’s management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and the Company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the Company’s most recent Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, including the sections entitled “Risk Factors”, as well the Company’s current reports on Form 8-K, filed with the Securities and Exchange Commission, and include the impact of the Company’s name change; the impact of the COVID-19 pandemic on the Company and its financial condition and results of operations; the effects of economic conditions on the Company’s business; the effects of the Affordable Care Act and potential changes thereto or a repeal thereof; the Company’s relationships with government-sponsored or funded healthcare programs, including Medicare and Medicaid, and with managed care organizations and commercial health insurance payors; the impact of surprise billing legislation and its implementation; the Company’s ability to comply with the terms of its debt financing arrangements; the Company’s transition to a third-party revenue cycle management provider; the impact of the divestiture of the Company’s anesthesiology and radiology medical groups; the impact of management transitions; the timing and contribution of future acquisitions; the effects of share repurchases; and the effects of the Company’s transformation initiatives, including its reorientation on, and growth strategy for, its pediatrics and obstetrics business.

Pediatrix Medical Group, Inc. Consolidated Statements of Income (in thousands, except per share data) (Unaudited)
		Three Months Ended June 30,								Six Months Ended June 30,
		2022				2021				2022				2021
Net revenue		$	486,033			$	472,959			$	968,262			$	919,712
Operating expenses:
Practice salaries and benefits			330,757				317,035				673,912				636,047
Practice supplies and other operating expenses			29,843				24,182				58,332				46,394
General and administrative expenses			61,165				70,968				122,452				137,484
Gain on sale of building			—				(7,280	)			—				(7,280	)
Depreciation and amortization			8,775				8,106				17,544				16,137
Transformational and restructuring related expenses			5,338				9,932				6,759				14,810
Total operating expenses			435,878				422,943				878,999				843,592
Income from operations			50,155				50,016				89,263				76,120
Investment and other income			844				4,176				1,719				10,143
Interest expense			(8,409	)			(16,879	)			(20,227	)			(34,524	)
Loss on early extinguishment of debt			—				—				(57,016	)			(14,532	)
Equity in earnings of unconsolidated affiliate			443				577				948				1,072
Total non-operating expenses			(7,122	)			(12,126	)			(74,576	)			(37,841	)
Income from continuing operations before income taxes			43,033				37,890				14,687				38,279
Income tax provision			(12,332	)			(7,363	)			(4,931	)			(2,408	)
Income from continuing operations			30,701				30,527				9,756				35,871
(Loss) income from discontinued operations, net of tax			(3,565	)			4,478				(3,812	)			16,768
Net income			27,136				35,005				5,944				52,639
Net loss attributable to noncontrolling interest			—				6				4				14
Net income attributable to Pediatrix Medical Group, Inc.		$	27,136			$	35,011			$	5,948			$	52,653
Per common and common equivalent share data (diluted):
Income from continuing operations		$	0.36			$	0.36			$	0.11			$	0.42
(Loss) income from discontinued operations		$	(0.04	)		$	0.05			$	(0.04	)		$	0.19
Net income attributable to Pediatrix Medical Group, Inc.		$	0.32			$	0.41			$	0.07			$	0.61
Weighted average common shares			85,619				85,933				85,914				85,653

Pediatrix Medical Group, Inc. Reconciliation of Income from Continuing Operations to Adjusted EBITDA from Continuing Operations Attributable to Pediatrix Medical Group, Inc. (in thousands) (Unaudited)
		Three Months Ended June 30,								Six Months Ended June 30,
		2022				2021				2022				2021
Income from continuing operations attributable to Pediatrix Medical Group, Inc.		$	30,701			$	30,533			$	9,760			$	35,885
Interest expense			8,409				16,879				20,227				34,524
Gain on sale of building			—				(7,280	)			—				(7,280	)
Loss on early extinguishment of debt			—				—				57,016				14,532
Income tax provision			12,332				7,363				4,931				2,408
Depreciation and amortization expense			8,775				8,106				17,544				16,137
Transformational and restructuring related expenses			5,338				9,932				6,759				14,810
Adjusted EBITDA from continuing operations attributable to Pediatrix Medical Group, Inc.		$	65,555			$	65,533			$	116,237			$	111,016

Pediatrix Medical Group, Inc. Reconciliation of Diluted Income from Continuing Operations per Share to Adjusted Income from Continuing Operations per Diluted Share (“Adjusted EPS”) (in thousands, except per share data) (Unaudited)
		Three Months Ended June 30,
		2022								2021
Weighted average diluted shares outstanding		85,619								85,933
Income from continuing operations and diluted income from continuing operations per share attributable to Pediatrix Medical Group, Inc.		$	30,701			$	0.36			$	30,533			$	0.36
Adjustments (1):
Amortization (net of tax of $541 and $576)			1,624				0.02				1,728				0.02
Stock-based compensation (net of tax of $1,084 and $1,434)			3,252				0.04				4,301				0.04
Transformational and restructuring expenses (net of tax of $1,335 and $2,483)			4,003				0.05				7,449				0.09
Gain on sale of building (net of tax of $1,820)			—				—				(5,460	)			(0.06	)
Net impact from discrete tax events			294				—				(3,516	)			(0.04	)
Adjusted income and diluted EPS from continuing operations attributable to Pediatrix Medical Group, Inc.		$	39,874			$	0.47			$	35,035			$	0.41
(1) A blended tax rate of 25% was used to calculate the tax effects of the adjustments for the three months ended June 30, 2022 and 2021.

		Six Months Ended June 30,
		2022								2021
Weighted average diluted shares outstanding		85,914								85,653
Income from continuing operations and diluted income from continuing operations per share attributable to Pediatrix Medical Group, Inc.		$	9,760			$	0.11			$	35,885			$	0.42
Adjustments (1):
Amortization (net of tax of $1,082 and $1,466)			3,245				0.04				4,400				0.05
Stock-based compensation (net of tax of $2,193 and $2,363)			6,578				0.07				7,089				0.08
Transformational and restructuring expenses (net of tax of $1,690 and $3,702)			5,069				0.06				11,108				0.13
Gain on sale of building (net of tax of $1,820)			—				—				(5,460	)			(0.06	)
Loss on early extinguishment of debt (net of tax of $14,254 and $3,633)			42,762				0.50				10,899				0.13
Net impact from discrete tax events			786				0.01				(8,583	)			(0.10	)
Adjusted income and diluted EPS from continuing operations attributable to Pediatrix Medical Group, Inc.		$	68,200			$	0.79			$	55,338			$	0.65
(1) A blended tax rate of 25% was used to calculate the tax effects of the adjustments for the six months ended June 30, 2022 and 2021.

Pediatrix Medical Group, Inc. Balance Sheet Highlights (in thousands) (Unaudited)
		As of June 30, 2022				As of December 31, 2021
Assets:
Cash and cash equivalents		$	14,088			$	387,391
Investments			93,386				99,715
Accounts receivable, net			307,201				301,775
Income taxes receivable			21,529				14,249
Other current assets			23,097				37,434
Intangible assets, net			20,965				21,565
Operating and finance lease right-of-use assets			67,504				65,461
Goodwill, other assets, property and equipment			1,821,846				1,794,956
Total assets		$	2,369,616			$	2,722,546
Liabilities and equity:
Accounts payable and accrued expenses		$	287,463			$	394,118
Total debt, including finance leases, net			808,176				1,004,748
Operating lease liabilities			62,667				61,080
Other liabilities			365,880				365,908
Total liabilities			1,524,186				1,825,854
Total equity			845,430				896,692
Total liabilities and equity		$	2,369,616			$	2,722,546

Pediatrix Medical Group, Inc. Reconciliation of Income from Continuing Operations to Forward-Looking Adjusted EBITDA from Continuing Operations Attributable to Pediatrix Medical Group, Inc. (in thousands) (Unaudited)
		Year Ended December 31, 2022
Income from continuing operations attributable to Pediatrix Medical Group, Inc.		$	86,000			$	95,000
Interest expense			38,000				36,000
Loss on early extinguishment of debt			57,000				57,000
Income tax provision			35,700				38,700
Depreciation and amortization expense			34,000				34,000
Transformational and restructuring related expenses			9,300				9,300
Adjusted EBITDA from continuing operations attributable to Pediatrix Medical Group, Inc.		$	260,000			$	270,000

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20220804005290/en/

Charles Lynch

Senior Vice President, Finance and Strategy

954-384-0175, x 5692

charles.lynch@pediatrix.com

Source: Pediatrix Medical Group, Inc.

FAQ

What were Pediatrix's earnings for Q2 2022?

Pediatrix reported earnings from continuing operations of $0.36 per share for Q2 2022.

How did Pediatrix's revenue perform in Q2 2022?

The company reported net revenue of $486 million for Q2 2022, a 2.7% increase from the prior year.

What is the projected Adjusted EBITDA for Pediatrix in 2022?

Pediatrix anticipates its 2022 Adjusted EBITDA to be between $260 million and $270 million.

What were the Adjusted EPS for Pediatrix in Q2 2022?

Pediatrix reported an Adjusted EPS of $0.47 for Q2 2022, up from $0.41 in Q2 2021.

What is the impact of acquisitions on Pediatrix's financials?

Acquisitions contributed to a revenue increase, but operating expenses also rose significantly due to these acquisitions.